Ernexa Therapeutics Inc. (ERNAW) Operating income 2016–2025
Ernexa Therapeutics Inc. (ERNAW) annual operating income history from SEC filings — each fiscal year as reported.
-$9.3MFY2025 · since FY2016: -$2.3M → -$9.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$9.3M | +40.5% |
| FY2024 | -$15.7M | +25.8% |
| FY2023 | -$21.1M | +36.4% |
| FY2022 | -$33.2M | +70.8% |
| FY2021 | -$113.7M | -1469.2% |
| FY2020 | -$7.2M | -311.4% |
| FY2019 | -$1.8M | -968.0% |
| FY2018 | $203,000 | +114.5% |
| FY2017 | -$1.4M | +38.5% |
| FY2016 | -$2.3M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ERNAW financial trends
ERNAW RevenueERNAW Net incomeERNAW Net marginERNAW Gross profitERNAW Gross marginERNAW Operating marginERNAW Operating cash flowERNAW Free cash flowERNAW Capital expendituresERNAW Return on equityERNAW Stock buybacksERNAW Dividends paidERNAW Total assetsERNAW Total liabilitiesERNAW Shareholders’ equityERNAW overview →